Antiretroviral therapy during the earliest stage of acute HIV infection (Fiebig I) might minimize establishment of a latent
HIV reservoir and thereby facilitate viremic control after analytical treatment interruption. We show that 8 participants, who initiated treatment during Fiebig I and were treated for a median of 2.8 years, all experienced rapid viral load rebound following analytical treatment interruption, indicating that additional strategies are required to control or eradicate HIV.
HIV latency is established during acute HIV infection in longlived CD4
+ T cells and other cell types in blood and tissue sanctuaries [1] [2] [3] . These reservoirs pose a major obstacle to HIV remission (viremic control without antiretroviral therapy (ART)). Despite viral suppression by ART, most individuals experience viral load rebound within two to four weeks of stopping ART. HIV remission appears more common in a limited number of early-treated individuals analyzed 4 . Fiebig I stage corresponds to the first two weeks following infection when HIV nucleic acid is detected in the absence of p24 antigen (viral capsid core protein) and HIV seroconversion. The brevity of this period and non-reactivity to HIV serologic testing means that HIV is rarely diagnosed in Fiebig I. Treatment in these individuals can lead to preserved immunity, remarkably low HIV reservoir size and no seroconversion 5, 6 , but its impact on post-treatment control is unknown. This study evaluated viremic control after analytical treatment interruption (ATI) in Fiebig I treated individuals, and had planned to enroll 15 participants in 2 stages: 8 in stage 1 and 7 in stage 2. It was stopped after stage 1 when 0 of 8 participants met the viremic control end point ( Supplementary Fig. 1 ). This study provides proof-of-concept that viral load rebound will occur despite very early and fully suppressive ART. The sample size of eight participants did not preclude a rate of control below 30%.
At enrollment, there were 7 men and 1 woman with a median age of 29 years, an ART duration of 2.8 years, a CD4 + T count of 577 cells per mm 3 and a suppressed viral load (Supplementary Table 1 ). All had been on efavirenz-based ART and switched from efavirenz to darunavir/ritonavir 4 weeks prior to ATI to limit resistance to that drug class. No participant achieved viral load < 50 copies per ml at 24 weeks post ATI. All resumed ART following two viral load measurements > 1,000 copies per ml, ranging from 1 to 2 d apart per protocol. Viral load rebound, defined as viral load > 20 copies per ml, was observed at a median of 26 d (range 13-48 d) ( Fig. 1a and Supplementary Fig. 2 ). Single copy viral load assay (SCA) on samples with viral load < 20 copies per ml showed viral load < 0.45 copies per ml at baseline in all participants, and two had detectable SCA during ATI prior to viral load rebound ( Supplementary Fig. 3 ).
CD4/CD8 ratio ≤ 1 was associated with faster time to viral load rebound in a study of early treated people 7 . We also observed this in treated Fiebig I individuals (Fig. 1b) . The median CD4 + T cell change at ART resumption was -9 (range -87 to 39) cells per mm 3 . No participant had acute retroviral syndrome, HIV-related symptoms or new drug resistance mutations (Supplementary Information and  Supplementary Table 2 ). Viral load was < 50 copies per ml in all participants by a median of 17 d (range 9-63) after ART resumption.
Phylogenetic analyses showed that sequences at time of ART initiation in acute infection and at ART resumption following viral load rebound were intermingled in the trees, with no evidence of distinct sub-clusters ( Fig. 1c and Supplementary Fig. 4a-c .
The frequencies of blood CD4
+ T cells harboring total HIV DNA were low pre-ART (median 66 copies per 10 6 CD4 + T cells, interquartile range (IQR) 22-281) and pre-ATI (median 1 copy per 10 6 CD4 + T cells, IQR 1-3) (Fig. 2a) . Prior to ATI, our participants had an estimated ~2 × 10 6 CD4 + T cells that harbored HIV DNA in the whole body. Total HIV DNA increased to a median of 17 copies per 10 6 CD4 + T cells (IQR 6-60) at the time of ART resumption (P = 0.03 compared to pre-ATI). However, 6 months after resuming ART, total HIV DNA returned to a median of 3 copies per 10 6 CD4 + T cells (IQR 2-10), similar to pre-ATI levels (P = 0.33) (Fig. 2a) , and demonstrating safety of this ATI strategy with a short duration of viremia. The total and integrated HIV DNA of individual participants showed similar patterns and returned to approximate pre-ATI values ( Supplementary Fig. 5 ). Inducible HIV RNA by the Tat/rev Induced Limiting Dilution Assay (TILDA) showed pre-ATI levels below the detection limit of 1.4 cells producing tat/rev mRNA per 10 6 CD4 + T cells in all participants.
In this small study, there was no association between pre-ATI total HIV DNA and time to viral load rebound 10 (Fig. 2b) . Similarly, pre-ATI integrated HIV DNA and 2-LTR (long terminal repeat) circles, which reflect HIV reservoir maintenance and putatively residual replication, respectively, did not predict time to viral load rebound, nor did any of the HIV reservoir markers (total and integrated HIV DNA, 2-LTR circles) assessed at pre-ART ( Supplementary  Fig. 6a-c) . A very low frequency of HIV-infected memory CD4
+ T cells at time of ART resumption was observed among the four participants assessed, with LTR or gag RNA + cells present at 0.001-0.01% ( Supplementary Fig. 7a,b) . HIV DNA content in mucosal mononuclear cells from sigmoid tissue (n = 3) was also low at pre-ATI and at ART resumption (Supplementary Information). HIV RNA Reactivation of a single latently infected cell can lead to viral load rebound in the absence of ART. One mathematical model postulates that control of viremia may depend on the strength of cytotoxic T lymphocytes (CTLs) and the size of the HIV reservoir 11 . We posit that the rapid viral load rebound observed in this study was due to the inability to achieve a small enough pool of latently infected cells 12 , particularly in lymphoid tissues 13 , and inadequate immune control 11 . The reservoir in acute HIV infection may also be enriched in replication competent viruses, facilitating viral rebound 14 . We previously reported that CTLs generated in Fiebig I are less abundant and differentiated than in later stages, but retain greater memory and survival potential 6 . We therefore investigated persistence and recall of memory immune responses during ART and post ATI. In three participants expressing HLA-A11, the memory HIV-specific CTLs quantified longitudinally by tetramer staining 6 persisted at low levels years after suppressive ART, and their expansion occurred faster following viral load rebound than in acute HIV infection ( Supplementary  Fig. 10a-d) . In all participants, there was a rapid expansion of effector Ki67 + CD8 + T cells at ART resumption (median 12.4%) to frequencies higher than those at baseline ATI (median 5.4%, P = 0.01) (Fig. 2c) . Env-specific immunoglobulin (Ig) G level was higher at ART resumption than in acute infection in 7 of 8 participants (median 98 versus 34 µ g per ml, P = 0.04) (Fig. 2d) . Four of these 7 had increased levels from baseline ATI to ART resumption (median 37.8 to 187.2 µ g ml -1 , P = 0.07) and seroconverted after ATI ( Supplementary Fig. 11 ), suggesting a memory B cell response. Prior to ART resumption, the highest observed plasma viral load levels were negatively associated with the frequency of effector Ki67 + CD8 + T cells (r = -0.83, P = 0.02; Fig. 2e ) and Env-specific IgG levels (r = -0.86, P = 0.01; Fig. 2f) . It is therefore possible that pre-ATI immune responses were "too little too late" to affect time to viral load rebound, but were sufficient to affect the magnitude of viremia once expansion of HIV-specific 
CD8
+ T cells and secretion of Env-specific IgG occurred. Our stringent ART resumption criterion based on viral load precluded assessing the effects of early ART on spontaneous viral load resuppression after rebound. It was demonstrated previously that an initial sustained viremia (highest viral load 10 3 -10 7 copies per ml) was followed by viral load < 40 copies per ml in 2 of 15 (13%) early treated participants at 10 months post ATI 15 . The optimal design and conduct of ATI trials is unknown, but can be informed by ongoing dialogues between researchers, the community, ethicists, social scientists, and regulatory bodies.
Our study documented that in eight participants, ART initiated in Fiebig I did not prevent viral load rebound. Regardless of timing of ART, future research should aim to eliminate cells with replication competent HIV in blood and tissues through augmenting immune responses (for example, through the administration of latency reversal or immune adjuvant agents, broadly neutralizing antibodies (bNAbs), therapeutic vaccines or cell-based therapies) 16 . Early administration of immune interventions during acute infection should be explored as demonstrated in macaques to improve viral load control 17, 18 . Limited viral escape in acutely treated individuals may enhance the responses to such interventions. Combination therapies (for example, multiple bNAbs and immune modulators) should be investigated as single bNAb administration in acutely and chronically treated people did not substantially delay viral load rebound 19 .
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41591-018-0026-6. + T cells prior to ATI was not significantly associated with time to viral load rebound > 20 copies per ml post-ATI. Open symbols depict levels below the limit of detection of the assay. c, Effector Ki67
+ T cells expanded rapidly following viral load rebound in all participants. The percentage of Ki67 + cells in CD45RA -CD8 + T cells is shown. d, Envelope (ENV)-specific IgG levels were higher following viral load rebound than at AHI pre-ART in 4 participants (4617, 6054, 6579, 4878). e,f, The frequencies of Ki67 + CD8 + T cells (e) and plasma ENV-IgG levels (f) were negatively associated with the highest observed viral load levels at ART resumption. 18 
The RV411 study (clinicaltrials.gov NCT02614950) included eight consenting participants who initiated ART during Fiebig I acute HIV infection in the RV254 cohort in Thailand (clinicaltrials.gov NCT00796146) 20 , and had been on ART for ≥ 96 weeks. Inclusion criteria included viral load < 50 copies per ml for at least 48 weeks, integrated HIV DNA in peripheral blood mononuclear cells (PBMCs) of < 10 copies per 10 6 PBMCs, and CD4 + T cells of ≥ 400 cells per mm 3 . Exclusion criteria were pregnancy, breastfeeding, untreated syphilis, hepatitis B or C infection, active drug or alcohol use, or serious medical or psychiatric condition that could interfere with study participation. They were staged for acute HIV infection at time of ART initiation according to Fiebig et al. 21 Fiebig I is defined as HIV RNA + , p24 antigen -, HIV IgM -). The participants underwent analytical treatment interruption (ATI) at baseline and were followed for 24 weeks or until they reached ART resumption criteria. ART resumption criteria included confirmed viral load > 1,000 copies per ml, viral load rise of ≥ 0.5 log 10 copies per ml per day provided that the last viral load was > 1,000 copies per ml, a single viral load > 10,000 copies per ml, confirmed CD4 + T cell < 350 cells per mm 3 , CD4 + T cell count decline > 50% from baseline prior to ATI, acute retroviral syndrome, clinical progression to CDC category B or C disease, pregnancy or request by the participant. The study planned to enroll 15 participants in 2 stages: 8 in stage 1 and 7 in stage 2. However, this study did not reach the criterion to proceed to stage 2 of at least 1 participant in stage 1 achieving viral load < 50 copies per ml at 12 weeks post-ATI ( Supplementary Fig. 1 and Supplementary Information).
The primary objective was to determine if the rate of sustained viral suppression < 50 copies per ml was significantly higher than 5% at 24 weeks after ATI. Specifically, we hypothesized that ≥ 30% would maintain plasma viral load < 50 copies per ml at 24 weeks post ATI. Assessment of safety, time to ART resumption, viral load kinetics, HIV DNA reservoir, and HIV-specific immune responses constituted secondary objectives. Optional sigmoid and lymph node biopsies were performed in willing participants at baseline ATI and/or prior to ART resumption. The study was approved by the Institutional Review Boards of Chulalongkorn University in Thailand, University of Montreal in Canada, University of California San Francisco, and Walter Reed Army Institute of Research in the United States. The study received non-human subject research determination from Drexel University and the National Institutes of Health in the USA. The investigators have adhered to the policies for protection of human participants as prescribed in AR-70.
All RV411 participants were on efavirenz-based regimens prior to enrollment in the study, and some participants also received raltegravir and maraviroc during the first 24 weeks of ART in the RV254 study. Efavirenz was replaced with darunavir/ritonavir 4 weeks prior to ATI to limit the risk for development of genotypic resistance to the non-nucleoside reverse transcriptase inhibitor drug class (Supplementary Table 1 ).
Measurement of HIV RNA.
Quantitative plasma viral load by the COBAS Taqman HIV-1 Test with a limit of detection of 20 copies per ml (Roche Diagnostics) was monitored weekly except from weeks 2 to 6, when it was monitored twice weekly. In order to alleviate participants' discomfort, qualitative nucleic acid testing (Aptima HIV-1 RNA Qualitative Assay, Hologic Inc.) by finger stick was also used during the twice weekly monitoring and at weekly monitoring visits when venapuncture was not required for additional laboratory testing. Any positive Aptima was confirmed with quantitative viral load.
For single copy HIV RNA, 3 ml of plasma was assayed using HMMCgag primers and probes optimized for CRF01_AE clade 22 with a limit of detection of 0.45 copies per ml according to methods previously described 23 .
HIV genotyping. HIV genotyping was performed to detect mutations in the reverse transcriptase (RT) and protease (PR) genes at pre-ART and at time of ART resumption following ATI. TRUGENE (Siemens Healthcare Diagnostics, Bayswater, Victoria, Australia) was used for the pre-ART samples of 3 participants (4617, 7010, 8534). All other genotype testing used a validated in-house method as previously described 24 . Genotype sequences were analyzed using the Stanford University Drug Resistance Database 25 .
HIV sequencing. HIV-1 pro-RT (HXB2 corresponding numbers 2071-3870) and envelope gp160 (5956-9089) were amplified from plasma RNA following our previously described single genome amplification strategy 26 adapted from Salazar-Gonzalez 27 . A nested PCR strategy was employed with primers specific for CRF01_AE and subtype B. cDNA synthesis was performed using JL68Rv2 (CTT CTT CCT GCC ATR KGA RAT GCC TAA G) for pro-RT and oligodT20 for gp160. First round primers were polRT2071F (GAR AGR CAG GCT AAT TTT TTA GG) and polG_AGrev (TRT CTA CTT GTT CAT TTC CYC C) for pro-RT; polK3 (TAA ARY TAG CAG GAA GAT GGC CAG T) and uninef7 (GCA CTC AAG GCA AGC TTT ATT GAG GCT T) for gp160. Second round primers were polRT2071F (GAR AGR CAG GCT AAT TTT TTA GG) and polRT3870R (CTA TTR GCT GCC CCA TCT ACA TA) for pro-RT, JL68 (CTT AGG CAT CTC CTA TGG CAG GAA GAA G) and JL89 (TCC AGT CCC CCC TTT TCT TTT AAA AA) for gp160.
Measurements of HIV DNA and TILDA in blood and tissues. Total and integrated HIV DNA were measured in CD4
+ T cells enriched from PBMCs (StemCell) using a nested PCR for LTR-gag designed to amplify the clades circulating in Thailand, with a sensitivity of 1 copy per PCR reaction 28 . Multiple replicates were performed and average total numbers of 1.2 × 10 6 cells (range 1.4 × 10 5 to 9.6 × 10 6 cells) and 1.4 × 10 5 cells (range 4.5 × 10 4 to 4.3 × 10 5 cells) were analyzed for determinations of total and integrated HIV DNA, respectively. Larger numbers of cells from the baseline time points were used for quantification of total HIV DNA (mean 2.5 × 10 6 (range 1.1 × 10 6 to 5.1 × 10 6 cells)). Total number of infected cells in the peripheral blood was estimated by taking into account the frequency of CD4 + T cells and assuming a total number of CD4 + T cells of 202.5 × 10 9 cells in the body. HIV DNA in mucosal mononuclear cells from sigmoid tissue obtained from four participants and lymph node mononuclear cells (LNMCs) obtained from inguinal lymph node tissue from one participant was performed using the same method.
Tat/rev Induced Limiting Dilution Assay (TILDA) was performed as previously described with modifications of the primers and probes for efficient amplification of tat/rev from the A/E subtype 29 . tat1.4AE (TGG CAG GAA GAA GCG GAA G) and revAE (TGT CTC TGY CTT GCT CKC CAC C) were used for reverse transcription and pre-amplification. tat2AE (GCA GTA AGG ATC ATC AAA ATC CTA TAC CAG AGC A), revAE and probe MSHIVFAMzenAE (56-FAM/ TTC YTT CGG/ZEN/GCC TGT CGG GTT CC/3IABkFQ) were used for the realtime PCR.
Measurements of HIV RNA
+ and HIV DNA + cells in inguinal lymph node tissue. Using HIV-specific riboprobes and in situ hybridization, HIV RNA-positive and HIV DNA-positive cells in lymph nodes were quantified by quantitative image analysis as previously described 30 .
Measurements of frequencies of HIV RNA
+ CD4 + T memory T cells. CD4
T cells were FACS sorted directly ex vivo into 200-400 replicate 1,000-cell wells (2 to 4 × 10 5 cells analyzed) for One-step RealTime RT-PCR cDNA synthesis and pre-amplification as previously described 31 (ThermoFisher). In addition to antibodies listed above, cells were stained with CD3-BV711 (clone UCHT1), CD14-BV510 (clone M5E2), CD16-BV510 (clone 3G8), CD20-BV510 (clone 2H7), CD45RO-BV650 (clone UCHL1), all BioLegend, and CD45RA-FITC (clone HI100, BD Biosciences). Quantitation of HIV genes was performed by qPCR. The frequency of 1,000-cell replicate wells positive for any viral gene was < 1%. Therefore a positive well was unlikely to contain more than one positive cell and thus was counted as a single positive cell. Kit lysis does not efficiently extract nucleic acid residing in the nucleus, as measured by Alu-LTR detection of integrated viral DNA 32 . As such we interpret the qPCR values for gag and LTR to reflect cytoplasmic nucleic acid, which is expected to be predominantly RNA, but may include unintegrated proviral DNA as well. The env assay is specific for spliced RNA as the probe spans the splice junction. qPCR oligo sequences were as follows: LTR (adapted from ref. 28 ) F, CTG GGT CTC TCT DGT TAG AC; R, CTG AGG GAT CTC TAG TTA CC; P, CAC TCA AGG CAA GCT TTA TTG AGG C; gag F, CAT TAG AAG ARA TGA TGA CAG CAT; R, GCT CAT TGC CTC RGC YAA AAC; P, AGT RGG AGG ACC TRG CCA TAA RGC AAG; env F, CTG MGG TGC ACA CAG CAA GA; R, GAG GAG KTC YTC GTC GGT G; P, TTC CGC TTC TTC CAG TCG CCG CTC T.
Antibodies and reagents for flow cytometry. Alexa Fluor 700-labeled anti-CD3, BUV496-labeled anti-CD4, allophycocyanin H7-labeled anti-CD45RA, and BUV395-labeled anti-Ki-67 were obtained from BD Biosciences. BV785-labeled anti-CD8, BV650-labeled anti-CD127, and Pacific Blue-labeled anti-Perforin came from BioLegend. Foxp3/Transcription Factor Staining Buffer Set was from eBioscience. HLA-A*1101 HIV-1 NEF (GAFDLSFFLK) soluble biotinylated monomers were produced at Chulalongkorn University (Bangkok, Thailand) as previously described 33 and tetramerized with PE-conjugated extravidin (SigmaAldrich). LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (LIVE/DEAD) was from Thermo Fisher Scientific (Molecular Probes).
Flow cytometry analysis. For general phenotyping, thawed PBMCs and LNMCs were first stained with LIVE/DEAD at room temperature for 10 min then cell surface markers at 4 °C for 20 min. They were washed with PBS containing 2% fetal bovine serum (washing buffer) twice, and then fixed and permeabilized with Foxp3/ Transcription Factor Staining Buffer Set. The cells were stained with antiKi-67 and anti-Perforin mAbs at room temperature for 30 min followed by washing twice with Foxp3 permeabilization buffer and washing buffer, respectively. For phenotypic analysis on antigen specific CD8 + T cells, thawed PBMCs were first stained with PE-labeled pMHC tetramer at 37 °C for 15 min. The cells were stained for the other cell surface markers at 4 °C for 20 min followed by washing twice with washing buffer. The cells were fixed/permeabilized and stained for Ki-67 and Perforin as mentioned earlier. All the stained cells were resuspended in PBS containing 2% formaldehyde before analysis on LSRII (BD Biosciences). All the flow cytometry data were analyzed with FlowJo v10 (FlowJo, LLC) (Supplementary Figure 12) . The sample size for this study was selected to provide adequate power to test the hypothesis that the true success rate was 5% versus the alternative that the success rate is 30%. A two stage design allowed for an interim assessment of success while controlling the overall type I error. Stage I included 8 participants and stage 2 included an additional 7 participants (totaling 15 participants). The minimax design minimized the maximum number of participants undergoing antiretroviral treatment interruption across both stages. The targeted Type I and Type II error rates for the minimax design were both 0.05 and under the current design, the actual Type I and Type II error rates were 0.034 and 0.147respectively, corresponding to an approximate 3.4% alpha and 85% power under the assumed alternative. The criterion to proceed from stage 1 and 2 was that at least 1 of 8 participants achieved VL < 50 at 12 weeks post treatment interruption. As none did, the study did not progress to stage 2, and a total of 8 participants were enrolled.
Data exclusions
Describe any data exclusions. No data were excluded from the analysis.
Replication
Describe whether the experimental findings were reliably reproduced.
Not applicable. Eight human participants were enrolled and underwent treatment interruption.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Not applicable. This is a phase 2, single-arm, open-label study.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section) For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
a. State the source of each eukaryotic cell line used. Not applicable. Cell lines were not used. 
Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
Description of research animals
Provide details on animals and/or animal-derived materials used in the study.
Not applicable. Research animals were not used.
Policy information about studies involving human research participants
Description of human research participants
Describe the covariate-relevant population characteristics of the human research participants.
8 human research participants were enrolled. There were 1 female and 8 male, and their median age was 29 years old. They all initiated antiretroviral therapy in acute HIV infection and had been virally suppressed for a median of 2.8 years prior to enrollment. 6 had CRF01_AE HIV infection and 2 had CRF01_AE/B infection.
